157 results
8-K
EX-99.1
FGEN
FibroGen Inc
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
a safety and tolerability profile that has supported ongoing clinical investigation in LAPC and metastatic pancreatic cancer. Pamrevlumab … and commercialization of roxadustat, including its commercial potential, and the potential safety and efficacy profile of roxadustat. These forward
8-K
EX-99.1
FGEN
FibroGen Inc
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
for the treatment of patients with LAPC. Pamrevlumab has demonstrated a safety and tolerability profile that has supported ongoing clinical investigation … of the company’s product candidates, the potential safety and efficacy profile of its product candidates, and its clinical programs. These forward-looking
8-K
EX-99.1
y87ak 4kaoecvlsjg
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
EX-99.1
d1104bpuspc2lo
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
f0t9 7zyx69suy
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
abgn19ivzlb90oq
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
EX-99.1
i8w cqhtnh5rwu
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
8-K
EX-99.1
5eefu wnan4
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
iyyw nqure
7 Nov 22
FibroGen Reports Third Quarter 2022 Financial Results
4:06pm